Advances in the Pharmacogenomics of Antiplatelet Therapy Background: Acute coronary syndrome (ACS) is a highly thrombotic state, and a sustained antiplatelet effect is vital to the prevention of thrombotic complications. Clopidogrel, the most widely used oral P2Y12 receptor antagonist in ACS, has attracted considerable attention because of significant variability in antiplatelet effect depending on the presence of CYP2C19 allele. Other P2Y12 receptor antagonists offer sustained and more predictable antiplatelet effects than clopidogrel albeit at an increased cost. Several studies have demonstrated the promising application of pharmacogenetics in choosing personalized antiplatelet therapy using the point-of-care genotype assays. Areas of Uncertainty: Guidelines regarding the genotype-guided approach to the selection of antiplatelet therapy have been conflicting, and studies evaluating the effect of pharmacogenetic-guided selection of antiplatelet therapy on the outcomes have demonstrated mixed results. Data Sources: A literature search was conducted using MEDLINE and EMBASE for studies reporting the association of pharmacogenetic-guided selection of antiplatelet therapy and the outcomes in patients with ACS until December 2018. Results: Presence of specific CYP2C19 allele significantly influences clopidogrel metabolism and associated outcomes in patients with ACS. Thrombotic and bleeding complications are more common in patients with loss-of-function (LOF) and gain-of-function (GOF) alleles, respectively. Although the pharmacogenetic-guided approach to the selection of antiplatelet therapy appears promising in ACS, studies have shown conflicting results, and direct randomized evidence linking this approach with the better outcomes is lacking. Conclusions: Genotype-guided selection of antiplatelet therapy is expected to be useful in patients undergoing percutaneous coronary intervention (PCI) with a high risk of adverse outcomes. The patient–physician discussion should be an essential part of this decision-making process. Large-scale multicenter randomized controlled trials using the point-of-care genotype assay are needed to investigate this approach further before its use can be recommended in all comers. Address for correspondence: Department of Internal Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL. E-mail: tausif.akhtar@gmail.com The authors have no conflicts of interest to declare. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Seizure Related to the Split Extended-Release Bupropion Tablets in a Young Female Patient No abstract available

Cytomegalovirus Pneumonia Causing Acute Respiratory Distress Syndrome After Brentuximab Vedotin Therapy No abstract available

Hypomagnesemia and Hypocalcemia Caused by Proton-Pump Inhibitors Long-Term Therapy No abstract available

The Efficacy of Hypnotherapy in the Treatment of Functional Dyspepsia Background: Functional dyspepsia (FD) is one of the most frequent functional gastrointestinal disorders and is defined using the Rome IV criteria as any combination of the following symptoms: postprandial fullness, early satiety, epigastric pain, and epigastric burning that are severe enough to interfere with the usual activities and occur at least 3 days per week over the past 3 months with an onset of at least 6 months before the presentation. The purpose of this systematic review is to analyze all the relevant studies in the literature that investigate the efficiency of hypnotherapy in FD. Areas Of Uncertainty: FD refractory to conservative treatment is a therapeutic challenge, and alternative treatment options are needed. Gut-oriented hypnotherapy has been reported an effective treatment for irritable bowel syndrome, but poorly tested in FD. Data Sources: We performed a search in 6 bibliographic databases (PubMed, Embase, Cochrane Library, Web of Science, Scopus, and LILACS) using customized search strategies for each engine. The search strategy included the following terms: (hypnosis, hypnotherapy, hypnotherapies, hypnogenesis, hypnotism, hypnotist, hypnotical suggestion, suggestion, and mesmerism) and {[functional and (dyspepsia or dyspeptic)] or FD}. Results: Taking the aforementioned criteria into account, the result was a review of 4 articles analyzing the efficacy of hypnotherapy in the treatment of FD, published in the past 20 years. The initial search identified 398 articles, of which 37 potentially appropriate articles were reviewed. Of these 37 articles, 4 articles were included in the review. The benefits observed by numerous studies go beyond the field of digestive pathology, patients describing a general improvement in physical and mental health. Conclusions: Current studies analyzing the efficacy of hypnotherapy in FD provide encouraging data, but additional randomized controlled trials are needed before a firm position on the effectiveness of hypnosis in FD. Address for correspondence: Popa Stefan-Lucian, PhD, MD, 2nd Medical Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, Second Medical Clinic, Clinicilor St, No. 3–5, Cluj-Napoca, Romania 400006. Email: popa.stefan@umfcluj.ro C. Giuseppe: Consulting/Speaker Board: Aboca, Alfa-Sigma, Allergan, Kiowa-Kirin, Malesci, Pharmextracta, Takeda. The remaining authors have no conflict of interest to disclose. All authors contributed significantly in all stages of this work, they have read and approved the manuscript and confirm that no conflict of interest exists. P. Stefan-Lucian supervised the study and has made substantial contributions to conception and correction of the drafts; C. Giuseppe critically revised the manuscript; D. L. Dumitrascu analyzed the data and made substantial contributions to the interpretation of data; D. Liliana revised the drafts and made contributions to the writing of the manuscripts. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Idiosyncratic Drug-Induced Liver Injury Secondary to Trimethoprim-Sulfamethoxazole No abstract available

Acute Renal Failure With Cocaine and SGLT-2 Inhibitor No abstract available

Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review Background: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta1-adrenergic antagonist, which has been extensively used since the 1970s. Areas of Uncertainty: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. Data Sources: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. Results: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. Conclusions: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF. Address for correspondence: Dragos Vinereanu, MD, PhD, FESC, FRCP, Department of Cardiology, University of Medicine and Pharmacy Carol Davila and University and Emergency Hospital, Splaiul Independentei 169 St, Bucharest 050098, Romania. E-mail: vinereanu@gmail.com Medical writing assistance for the development of this manuscript was funded by Recordati. D. Vinereanu reports research grants and personal fees from Recordati, Menarini, Astra-Zeneca, Merck, Pfizer, BMS, Novartis, Servier, and Terapia. A. Pathak reports grants and personal fees from Recordati. D. Kozlowski reports grants and personal fees from Sandoz, Pfizer, Astra-Zeneca, Recordati, and Berlin-Chemie. The remaining author has no conflict of interest to disclose. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Acetazolamide-Associated Idiosyncratic Simultaneous Bilateral Angle Closure and Cross-Sensitivity No abstract available

Acute Silver Toxicity From Colloidal Silver Overdose No abstract available